TSO3 — Investor Presentation (July 2016)
23 slides from TSO3's investor presentation, July 2016
Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing
TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation July 2016
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing
Slide 3: TSO3 - Our Vision
TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3
Slide 4: Where We Are From and Where We Are Going
Where We Are From and Where We Are Going TSX:TOS 2016 • Record revenue 2009 - 2014 • Reworked products • Record assembly capacity • Introduced STERIZONE® 125L+ • 91M shares oustanding1 and STERIZONE® VP4 Sterilizers • US$24.4M in cash2 • 18 sterilizers in operation at • Received flexible multi-chann
Slide 5: Purpose
Purpose TSX:TOS A Sterile Device for Every Procedure 5
Slide 6: Approach
Approach ity to Provide Sterile Sterilizer Devices to All Patients
Slide 7: Modernizing Healthcare Sterilization Technology
Modernizing Healthcare Sterilization Technology TSX:TOS Old Technology TSO3 Technology Low Temperature Sterilization Low Temperature Sterilization • 20+ year-old core technology The next generation industry technology • Operators must choose from several operating cycles Simple Single Cycle Oper
Slide 8: Multiple Large Target Markets
Multiple Large Target Markets TSX:TOS Existing Low-Temp Sterilizer Market NOW AVAILABLE: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Greenfield terminal sterilization opportunity for 75 million procedures annually in US & Europe by 20205 • Total equipment replacement
Slide 9: STERIZONE VP4 Sterilizer
STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error Proprietary Software automatically free cycle selection adjusts the steril
Slide 10: The Science – Patents Pending or Applied For
The Science – 36 Patents or Pending or Applied For TSX:TOS 10
Slide 11: Key Market Driver: Demographics
Key Market Driver: Demographics TSX:TOS Aging population to result in Aging Population Expected to Drive increasing demand for minimally Growth in MIS Surgeries and Endoscopies invasive diagnostic and surgical procedures (MIS)1 Global population is aging U.S. 65+ age group to grow 35%, from 40
Slide 12: Endoscopy Market
Endoscopy Market TSX:TOS “Despite reprocessing in accordance with US guidelines, viable Many endoscopes, including microbes and biologic debris persisted in clinically used [GI] colonoscopes and gastroscopes endoscopes, suggesting current reprocessing guidelines are not are not terminally steriliz
Slide 13: FDA Clearance of Extended Claims – an Industry First
FDA Clearance of Extended Claims – an Industry First TSX:TOS FDA has cleared the STERIZONE® VP4 July 2016: FDA cleared expanded indications Sterilizer for the sterilization of multi- for use of STERIZONE® VP4 Sterilizer to include: channeled flexible endoscopes (with a maximum of four channels) ha
Slide 14: Endoscopes & Superbugs
Endoscopes & Superbugs TSX:TOS SUPERBUG = Antimicrobial Resistant Bacteria 2 million+ Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1 CRE is resistant to most available antibiotics - up to 50% of infected patients die1 CRE infections increasingly prevalent and lin
Slide 15: Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements
Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements TSX:TOS Since multi-channeled flexible FDA Device Class endoscopes, including colonoscopes Highest Body Reprocessing and duodenoscopes are typically Contact Requirements Today Signaled not sterilize
Slide 16: Getinge Infection Control Exclusive Global Distribution Agreement
Getinge Infection Control Exclusive Global Distribution Agreement TSX:TOS “The STERIZONE® VP4 Sterilizer uniquely addresses an unmet global need for cost Getinge - exclusive global distributor rights to effective, high throughput sterilization of STERIZONE® VP4 Sterilizer complex medical devices u
Slide 17: Q1 2016 Financial Highlights – USD
Q1 2016 Financial Highlights – USD TSX:TOS Quarterly Revenue Q1 2016 Revenues a record $3.1M, primarily (US$ Millions) driven by 25 STERIZONE ® VP4 Sterilizers Shipped 25 STERIZONE® VP4 $3.1M shipped to Getinge Sterilizers to Getinge in the U.S. Gross Margin of 36% - indicating equipment margins
Slide 18: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TOS Stock Price (7/14/16) CAD $3.30 Total Revenue (ttm) $4.3M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low CAD $1.42-$3.49 Gross Profit (ttm) $0.9M Avg. Daily Vol. (3 mo.) 0.3M High-margin consumables and Net Loss (ttm
Slide 19: TSO3 Key Takeaways
TSO3 Key Takeaways TSX:TOS STERIZONE® VP4 Sterilizer: The ONLY FDA-cleared medical device sterilizer validated to terminally sterilize colonoscopes and gastroscopes Global Distribution Partner Multiple breakthroughs in design, capability, effectiveness and operational cost to beat incumbent te
Slide 20: Contact Us
Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. Ron Both, Senior Managing Director 2505, avenue Dalton Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (
Slide 21: Appendix
Appendix + Bs
Slide 22: Important Regulatory Growth Driver
Important Regulatory Growth Driver TSX:TOS FDA identified flexible endoscopes as known source of infection and cause of death FDA has recorded 109 reports of infections or FDA safety communication: contamination related to bronchoscopes over the Design of endoscopic retrograde cholangio- pancrea
Slide 23: Growth Strategies
Growth Strategies TSX:TOS Support Getinge for global introduction and Medical Reprocessing Lifecycle commercialization of STERIZONE® VP4 Sterilizer Expand manufacturing/assembly operations Broaden product portfolio: Sterilizer products purpose-built for the operating room (OR) Iterations o